FDA Approves First Drug to Image Tau Pathology in Patients Being Evaluated for Alzheimer’s Disease - Drug Information Update

https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-image-tau-pathology-patients-being-evaluated-alzheimers-disease?utm_campaign=FDA%20Approves%20First%20Drug%20to%20Image%20Tau%20Pathology%20in%20Patients%20Being%20Evaluated%20for%20Alzheimer%E2%80%99s%20Disease&utm_medium=email&utm_source=Eloqua

FDA Approves First Drug to Image Tau Pathology in Patients Being Evaluated for Alzheimer’s Disease

Today, the U.S. Food and Drug Administration approved Tauvid (flortaucipir F18) for intravenous injection, the first drug used to help image a distinctive characteristic of Alzheimer’s disease in the brain called tau pathology. Tauvid is a radioactive diagnostic agent for adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease. Tauvid is indicated for positron emission tomography (PET) imaging of the brain to estimate the density and distribution of aggregated tau neurofibrillary tangles (NFTs), a primary marker of Alzheimer’s disease. The most common adverse reactions in patients using Tauvid were headache, injection site pain and increased blood pressure. Tauvid is not indicated for use in the evaluation of patients for chronic traumatic encephalopathy (CTE).

Read More